Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription 19.07.2021 1 Am J Respir Crit Care Med 2 Ann Thorac Surg 3 BMC Cancer 2 Cancer 2 Cancer Res 1 Carcinogenesis 6 Chest 1 Clin Cancer Res 3 Clin Lung Cancer 2 Eur J Cardiothorac Surg 1 J Cancer Res Clin Oncol 1 J Clin Oncol 1 J Natl Cancer Inst 3 J Thorac Cardiovasc Surg 6 J Thorac Oncol 1 JAMA Oncol 1 Mol Cancer Ther 2 Oncologist 2 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Respir Crit Care Med

1. HUANG Y, Zhu M, Ji M, Fan J, et al
   Air Pollution, Genetic Factors and the Risk of Lung Cancer: A Prospective Study in the UK Biobank.
   Am J Respir Crit Care Med. 2021 Jul 12. doi: 10.1164/rccm.202011-4063.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

2. BLUMENTHALER AN, Hofstetter WL, Mehran RJ, Rajaram R, et al
   Preoperative Maximum Standardized Uptake Value Associated with Recurrence Risk In Early Lung Cancer.
   Ann Thorac Surg. 2021 Jul 9. pii: S0003-4975(21)01161.
   PubMed         Abstract available
   
   
3. WU W, He Z, Xu J, Wen W, et al
   Anatomical Pulmonary Sublobar Resection Based on Subsegment.
   Ann Thorac Surg. 2021;111:e447-e450.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. PARK K, Kim JS, Kim JH, Kim YC, et al
   An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
   BMC Cancer. 2021;21:802.
   PubMed         Abstract available
   
   
5. CHAU J, Yadav M, Liu B, Furqan M, et al
   Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
   BMC Cancer. 2021;21:808.
   PubMed         Abstract available
   
   
6. PASCOE J, Jackson A, Gaskell C, Gaunt C, et al
   Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).
   BMC Cancer. 2021;21:800.
   PubMed         Abstract available
   
   

   
   Cancer

7. PRINTZ C
   First person profile: John D. Minna, MD: This renowned lung cancer researcher continues pioneering treatments, inspiring his colleagues and trainees.
   Cancer. 2021;127:2605-2606.
   PubMed        
   
   
8. KHURI FR
   From Cancer to COVID, Boston to Beirut.
   Cancer. 2021;127:1172-1173.
   PubMed        
   
   

   
   Cancer Res

9. KASHIMA Y, Shibahara D, Suzuki A, Muto K, et al
   Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer.
   Cancer Res. 2021 Jul 9. pii: 0008-5472.CAN-20-2811.
   PubMed         Abstract available
   
   
10. VON ITZSTEIN MS, Gerber DE, Minna JD
    Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers.
    Cancer Res. 2021;81:3441-3443.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

11. CHEN W, Saxton B, Tessema M, Belinsky SA, et al
    Inhibition of GFAT1 in lung cancer cells destabilizes PD-L1 protein.
    Carcinogenesis. 2021 Jul 16. pii: 6322888. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Chest

12. PASQUINELLI MM, Tammemagi MC, Kovitz KL, Durham ML, et al
    Addressing Gender Disparities in Lung Cancer Screening Eligibility: USPSTF versus PLCOm2012 Criteria.
    Chest. 2021 Jul 9. pii: S0012-3692(21)01316-7. doi: 10.1016/j.chest.2021.
    PubMed         Abstract available
    
    
13. SEARS CR, Rivera MP
    Age, Sex, Smoking, and Race: Is Progress Being Made in Lung Cancer Screening Eligibility?
    Chest. 2021;160:31-33.
    PubMed        
    
    
14. BUEHLER KE, Wilshire CL, Gilbert CR, Gorden JA, et al
    Imaging Administrators: The Overlooked Barrier to Lung Cancer Screening Implementation.
    Chest. 2021 Jul 9. pii: S0012-3692(21)01313-1. doi: 10.1016/j.chest.2021.
    PubMed        
    
    
15. MAZZONE PJ, Silvestri GA, Souter LH, Caverly TJ, et al
    Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.
    Chest. 2021 Jul 9. pii: S0012-3692(21)01307-6. doi: 10.1016/j.chest.2021.
    PubMed         Abstract available
    
    
16. VAKIL E, Jackson N, Sainz-Zunega PV, Molina S, et al
    Optimizing diagnostic and staging pathways for suspected lung cancer: a decision analysis.
    Chest. 2021 Jul 10. pii: S0012-3692(21)01314-3. doi: 10.1016/j.chest.2021.
    PubMed         Abstract available
    
    
17. MAZZONE PJ, Silvestri GA, Souter LH, Caverly TJ, et al
    Screening for Lung Cancer: CHEST Guideline and Expert Panel Report - Executive Summary.
    Chest. 2021 Jul 9. pii: S0012-3692(21)01304-0. doi: 10.1016/j.chest.2021.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

18. LUO J, Martucci VL, Quandt Z, Groha S, et al
    Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
    Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

19. SAITO G, Kono M, Koyanagi Y, Miyashita K, et al
    Significance of Brain Imaging for Staging in Patients With Clinical Stage T1-2 N0 Non-Small-Cell Lung Cancer on Positron Emission Tomography/Computed Tomography.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00145.
    PubMed         Abstract available
    
    
20. BARTA JA, Shusted CS, Ruane B, Pimpinelli M, et al
    Racial Differences in Lung Cancer Screening Beliefs and Screening Adherence.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00143.
    PubMed         Abstract available
    
    
21. TSUI DCC, Kavanagh BD, Honce JM, Rossi C, et al
    Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00148.
    PubMed        
    
    

    
    Eur J Cardiothorac Surg

22. JONES DR
    Neoadjuvant immunochemotherapy in surgically resectable non-small-cell lung cancer: surgical expertise required.
    Eur J Cardiothorac Surg. 2021;60:88-90.
    PubMed        
    
    
23. BERTOLACCINI L, Spaggiari L
    The land of the Lotus-eaters in the COVID-19 epidemic.
    Eur J Cardiothorac Surg. 2021;60:1-2.
    PubMed        
    
    

    
    J Cancer Res Clin Oncol

24. BRANCHER S, Ribeiro AE, Toporcov TN, Weiderpass E, et al
    The role of metformin on lung cancer survival: the first systematic review and meta-analysis of observational studies and randomized clinical trials.
    J Cancer Res Clin Oncol. 2021 Jul 15. pii: 10.1007/s00432-021-03728.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

25. ROTHSCHILD SI, Zippelius A, Eboulet EI, Savic Prince S, et al
    SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    J Clin Oncol. 2021 Jul 12:JCO2100276. doi: 10.1200/JCO.21.00276.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

26. CHOI E, Sanyal N, Ding VY, Gardner RM, et al
    Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.
    J Natl Cancer Inst. 2021 Jul 13. pii: 6320070. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

27. CORSINI EM, Mitchell KG, Correa A, Morris VK, et al
    Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy.
    J Thorac Cardiovasc Surg. 2021;162:296-305.
    PubMed         Abstract available
    
    
28. JONES DR, Wu YL, Tsuboi M, Herbst RS, et al
    Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.
    J Thorac Cardiovasc Surg. 2021;162:288-292.
    PubMed        
    
    
29. ROBINSON LA, Babacan NA, Tanvetyanon T, Henderson-Jackson E, et al
    Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas.
    J Thorac Cardiovasc Surg. 2021;162:274-284.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

30. JASSEM J, de Marinis F, Giaccone G, Vergnenegre A, et al
    Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02286.
    PubMed         Abstract available
    
    
31. ROLFO C, Mack P, Scagliotti GV, Aggarwal C, et al
    Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).
    J Thorac Oncol. 2021 Jul 8. pii: S1556-0864(21)02284.
    PubMed        
    
    
32. WANG Y, Li J, Chang S, Dong Y, et al
    Risk and influencing factors for subsequent primary lung cancer after treatment of breast cancer: a systematic review and two meta-analyses based on four million cases.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02293.
    PubMed         Abstract available
    
    
33. MYERS R, Brauer M, Dummer T, Atkar-Khattra S, et al
    High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02256.
    PubMed         Abstract available
    
    
34. POWELL SF, Rodriguez-Abreu D, Langer CJ, Tafreshi A, et al
    Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02287.
    PubMed         Abstract available
    
    
35. AI X, Wang Q, Cheng Y, Liu X, et al
    Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02290.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

36. GETTINGER SN, Redman MW, Bazhenova L, Hirsch FR, et al
    Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2021 Jul 15. pii: 2781889. doi: 10.1001/jamaoncol.2021.2209.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

37. MIRZAPOIAZOVA T, Xiao G, Mambetsariev B, Nasser MW, et al
    Protein phosphatase 2A as a therapeutic target in small cell lung cancer.
    Mol Cancer Ther. 2021 Jul 12. pii: 1535-7163.MCT-21-0013.
    PubMed         Abstract available
    
    

    
    Oncologist

38. GEORGE S, Bell EJ, Zheng Y, Kim R, et al
    The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
    Oncologist. 2021;26:e1205-e1215.
    PubMed         Abstract available
    
    
39. AYERS KL, Mullaney T, Zhou X, Liu JJ, et al
    Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
    Oncologist. 2021;26:e1226-e1239.
    PubMed         Abstract available
    
    

    
    Thorax

40. ZENG L, Xu Q, Yang N, Lizaso A, et al
    Third left pulmonary lobe.
    Thorax. 2021;76:525.
    PubMed        
    
    
41. TAN VSR, Li A, Seet JE, Lee P, et al
    Metastases from tracheal adenoid cystic carcinoma.
    Thorax. 2021;76:208-209.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: